Immunotherapy of metastatic renal cell carcinoma

Current Opinion in Urology

Volumn 7, Issue 5, 1997, Pages 252-258

  Ljungberg, Börje ^a   Henriksson, Roger ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; FLOXURIDINE; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LEVAMISOLE; RETINOIC ACID; VINBLASTINE;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; HUMAN; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; NATURAL KILLER CELL; NEPHRECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0030694824     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199709000-00002     Document Type: Review

References (50)

1. Hänninen EL, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma, risks and benefits in 215 consecutive single institution patients. J Urol 1996, 155:19-25.
2. Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP et al.: Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. J Clin Oncol 1996, 14:2234-2241.
3. Négrier S, Escudier B, Lasset C, Savary J, Douillard JY, Chevreau C, Ravaud A, Peny J, Mousseau M and the French Immunotherapy Group: The FNCLCC CRECY trial: interleukin 2 (IL2) + interferon (IFN) Is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC) [Abstract]. Proc Am Soc Clin Oncol 1996, 15:248.
4. Nieken J, Sleijfer DT, Buter J, deLeij L, Mulder NH: Outpatient based subcutaneous interleukin-2 monotherapy in advanced renal cell carcinoma. Cancer Biother Radiopharmaceut 1996, 11:289-295.
5. Canobbio L, Curotto A, Cannata D, Miglietta L, Lavarello A, Giglio C, Franchini R, Cussotto M, Boccardo F: Combination therapy with subcutaneous interleukin-2 and interferon-alfa in advanced renal cancer patients with poor prognostic factors. Anticancer Res 1996, 16:541-544.
6. Tourani JM, Lucas V, Mayeur D, Dufour B, Dipalma M, Boaziz C, Grise P, Varette C, Pavlovitch JM, Pujadelauraine E et al.: Subcutaneous recombinant interleukin-2 (RIL-2) in out-patients with metastatic renal cell carcinoma - results of a multicenter scapp1 trial. Ann Oncol 1996, 7:525-528.
7. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996, 14:2410-2411.
8. Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, Giedlin MA, Caligiuri MA: Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxiclty. Clin Cancer Res 1996, 2:669-677.
9. Hanson JP, Treisman J, LeFever A, Mikolajczak T, Rohloff C, Rausch C: Treatment of metastatic renal cell carcinoma with combination immunotherapy [Abstract]. Proc Am Soc Clin Oncol 1996, 15:264.
10. Figlin RA, Gitlitz BJ, Franklin J, Dorey F, Rauch J, deKernion J, Belldegrun A: Long term survival of patients with metastatic renal cell carcinoma treated with IL-2 based immunotherapy with or without tumor infiltrating lymphocytes: the UCLA kidney cancer program [Abstract]. Proc Am Soc Clin Oncol 1996, 15:265.
11. Yannelli JH, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M, Rosenberg SA: Growth of tumour-infiltrating lymphocytes from human solid cancers - summary of a 5-year experience. Int J Cancer 1996, 65:413-421.
12. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmüller HGW: Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J Urol 1996, 156:18-21.
13. Gitlitz BJ, Dolan N, Pierce W, deKernion J, Belldegrun A, Figlin RA: Fluoropyrimidines plus interleukin-2 and interferon-α in the treatment of metastatic renal cell carcinoma: the UCLA kidney cancer program [Abstract]. Proc Am Soc Clin Oncol 1996, 15:248.
14. Igarashi T, Marumo K, Onishi T, Kobayashi M, Satomi Y, Aiba K, Kawamura J: Interferon-alpha plus 5-FU therapy in metastatic renal cell cancer: a multicenter trial by the Japanese study group against renal cell cancer [Abstract]. Proc Am Soc Clin Oncol 1996, 15:257.
15. Elias L, Blumenstein BA, Kish J, Falnigan RC, Wade JL, Lowe BA, Goodwin JW, Crawford ED: A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma - a Southwest Oncology Group study. Cancer 1996, 78:1085-1088.
16. Falcone A, Cianci C, Pfanner E, Ricci S, Lencioni M, Brunetti I, Giulianotti PC, Vannucci L, Mosca F, Conte PF: Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant α2b-interferon. Ann Oncol 1996, 7:601-605.
17. Pyrhönen S, Salminen E, Lehtonen T, Nurmi M, Tammela T, Juusela H, Ruutu M, Kellokumpu-Lehtinen M: Recombinant interferon alfa-2a with vinblastine vs vinblastine alone in advanced renal cell carcinoma. A phase III study [Abstract]. Proc Am Soc Clin Oncol 1996, 15:244.
18. Whitehead RP, Blumenstein B, Flanigan RC, Weiss GR, Culkin DJ, Bearman SJI, Dakhil S, Crawford ED: Phase II trial of recombinant human interleukin-4 (rhuIL-4) in patients with disseminated renal cell adenocarcinoma: a Southwest Oncology Group (SWOG) study [Abstract]. Proc Am Soc Clin Oncol 1996, 15:259.
19. Spathschwalbe E, Schrezenmeier H, Bornstein S, Burger K, Prozsolt F, Born J: Endocrine effects of recombinant interleukin 6 in man. Neuroendocrinology 1996, 63:237-243.
20. Stouthard JML, Goey H, de Vries EGE, de Mulder H, Groenewegen A, Pronk L, Stoter G, Sauerwein HP, Bakker PJM, Veenhof CHN: Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial. Br J Cancer 1996, 73:789-793.
21. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RM: Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996, 88:38-43.
22. Steger GG, Djavanmard MP, Steiner B, Budinsky AC, Michl I, Brodowicz T, Krainer M, Blöchl-Daum B, Huber H, Marberger M, Zielinski C: Preliminary report of an ongoing phase II trial for advanced renal cell carcinoma (RCC) with interferon-γ(IFN-γ) and interleukin-2 (IL-2) [Abstract]. Proc Am Soc Clin Oncol 1996, 15:268.
23. Lummen G, Goepel M, Mollhoff S, Hinke A, Otto T, Rubben H: Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha-2b in metastatic renal cell carcinoma. J Urol 1996, 155:455-458.
24. deLima M, Ellerhorst J, Sella A, Amato R, Zukiwski A, Logothetis C: Phase II study of gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma [Abstract]. Proc Am Soc Clin Oncol 1996, 15:261.
25. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccinations with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci 1993, 90:339-343.
26. Wos E, Olencki T, Tuason L, Budd GT, Peereboom D, Sandstrom K, Mclain D, Finke J, Bukowski RM: Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma. Cancer 1996, 77:1149-1153.
27. Campos D, Balbiani L, Coppola F, Estevez R, Zori Comba A, Arrieta D, Guzmán Machado C, Caparrós A, Areco A, Martinez C et al.: Interferon alfa-2a (IFN) and 13-cis-retinoic acid (CRA) in advanced renal cell carcinoma, early results [Abstract]. Proc Am Soc Clin Oncol 1996, 15:266.
28. Stadler WM, Talabay K, Vogelzang NJ: Interleukin-2 (IL2), interferon-α(IFNa), and cis-retinoic acid (CRA): an effective outpatient regimen for metastatic renal cell carcinoma (RCC) [Abstract]. Proc Am Soc Clin Oncol 1996, 15:241.
29. Atzpodien, Buer J, Probst M, Duensing S, Kirchner H, Ganser A: Clinical and pre-clinical role of 13-cis-retinoic acid in renal cell carcinoma: Hannover experience [Abstract]. Proc Am Soc Clin Oncol 1996, 15:247.
30. Picus J, Walker PR, Webb C, Gonin R, Woodrupp J, McClean J: A phase II study of levamisole in the treatment of advanced renal cell cancer: A Hoosier Oncology Group study [Abstract]. Proc Am Soc Clin Oncol 1996, 15:260.
31. Ahmed FY, Leonard GA, Ahern R, Taylor AE, Lorentzos A, Atkinson H, Moore J, Nicolson MC, Riches PG, Gore ME: A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma. Br J Cancer 1996, 74:1109-1113.
32. Deckert M, Franzke A, Buer J, Probst M, Duensing S, Lopezhaenninen E, Kirchner H, Poliwoda H, Atzpodien J: Linomide and Interleukin-2 in patients with advanced renal cell carcinoma. Cancer Biother and Radiopharmaceut 1996, 11:319-324.
33. Hobart K, Hallas A, Steiner G, Gomahr A, Aulitzky W, Marberger M: Circulating immune markers in advanced renal cell carcinoma during immunotherapy with interferon gamma. Urol Res 1996, 24:101-106.
34. Gohring B, Riemann D, Rebmann U, Heynemann, Schabel J, Langner J: Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alfa-2 in combination with 5-FU. Urol Res 1996, 24:297-303.
35. Bain C, Merrouche Y, Puisieux I, Blay JY, Negrier S, Bonadona V, Lasset C, Lanier F, Duc A, Gebuhrer L et al.: Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Br J Cancer 1997, 75:283-286.
36. Lissoni P: Prognostic markers in interleukin-2 therapy. Cancer Biother & Radiopharmaceut 1996, 11:285-287.
37. Papadopoulos I, Rudolph P, Weichert-Jacobsen K, Thiemann O, Papadopoulou D: Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alfa-2 beta and vinblastin. Urology 1996, 48:373-378.
38. Belldegrun A, Tso CL, Kaboo R, Pang S, Pierce W, Dekernion JB, Figlin R: Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy. J Immunother 1996, 19:149-161. The patient's baseline natural immune status seems to predict the clinical response to TIL and IL-2-based immunotherapy. The percentage of circulating NK cells and the presence of serum NK-cell-enhancing factors may serve as predictors of response.
39. Duensing S, Vandenbergderuiter E, Störkel S, Kirchner H, Hanninen EL, Buer J, Poliwoda H, Atzpodien J: Cytogenetic studies in renal cell carcinoma patients receiving low-dose recombinant interleucin-2-based immunotherapy. Tumor Biol 1996, 17:27-33.
40. Joffe JK, Patel PM, Banks RE, Selby PJ: Cytokines in combination with chemotherapy for advanced renal carcinoma - the importance of patient selection. Cancer Biother and Radiopharmaceut 1996, 11:309-313.
41. McCaffrey JA, Motzer RJ: What is the role of nephrectomy in patients with metastatic renal cell carcinoma? Semin Oncol 1996, 23:19-21.
42. Marcus SG, Choyke PL, Reiter R, Jaffe GS, Alexander HB, Linehan WM, Rosenberg SA, Walther MM: Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993, 150:463-466.
43. O'Rielly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996, 2:689-692.
44. Tanquay S, Swanson DA, Putnam JB: Renal cell carcinoma metastases to the lung potential benefit in the combination of biological therapy and surgery. J Urol 1996, 156:1586-1598.
45. Tanquay S, Pisters LL, Lawrence DD, Dinney CPN: Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol 1996, 155:26-29. A retrospective evaluation of 16 patients with local tumour recurrence comparing surgical resection with a combined treatment with immunotherapy followed by surgery. A survival advantage for the combined therapy was seen.
46. Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW, Gause BL, Sharfman WH, Urba WJ et al.: A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. J Immunother 1996, 19:364-374.
47. Anton P, Kirchner H, Jonas U, Atzpodien J: Cytokines and tumor vaccination. Cancer Biother & Radiopharmaceut 1996, 11:315-318. A total of 208 patients with locally advanced renal cell carcinoma were given adjuvant treatment with autologous, Newcastle disease virus-modified and lethally irradiated tumour cells in combination with low-dose IL-2 and IFN-α Compared with historical results, the data showed evidence for an improvement in disease-free survival.
48. Walker LG, Wesnes KP, Heys SD, Walker MB, Lolley J, Eremin O: The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments. Eur J Cancer 1996, 32A:2275-2283.
49. Karp BI, Yang JC, Khorsand M, Wood R, Merigan TC: Multiple cerebral lesions complicating therapy with interleukin-2. Neurology 1996, 47:417-424.
50. Khanna C, Hasz DE, Klausner JS, Anderson PM: Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res 1996, 2:721-734. By the use of aerosolized IL-2 liposomes, a favourable toxicity profile was obtained, which might be of value in increasing the tolerability of immunotherapy.